Applied Health Economics and Health Policy

, Volume 8, Issue 5, pp 281–300

Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand

Original Research Article

Abstract

Introduction

Streptococcus pneumoniae (Sp.) is a leading cause of paediatric bacterial meningitis, pneumonia and acute otitis media, as is non-typable Haemophilus influenzae (NTHi) for acute otitis media. In 2008, a 7-valent conjugated pneumococcal vaccine (PCV7) was included in the New Zealand (NZ) childhood immunization schedule.

Objective

To estimate the potentially vaccine-preventable annual hospital admissions and cost to the NZ Government of paediatric admissions for pneumococcal disease and NTHi otitis media prior to the immunization programme.

Methods

Admissions (2000–7) and deaths (2000–5) in children aged <20 years with pneumococcal meningitis or bacteraemia, pneumonia or otitis media were identified in national datasets and linked by unique patient identifiers. New episodes of illness were defined as admissions occurring >30 days after discharge from a previous admission. Informed by the literature, pneumococcal pneumonia episodes were estimated at 33% of all-cause pneumonia admissions; Sp. and NTHi otitis media episodes were estimated jointly at 72% of otitis media admissions. Each episode was assigned a single diagnosis according to the following hierarchy: meningitis > bacteraemia > pneumonia > otitis media. Incidence rates for episodes were determined for 2000–7 (meningitis, bacteraemia and pneumonia) and 2006–7 (otitis media). Annual DRG-based costs for pneumococcal meningitis, bacteraemia, pneumonia and otitis media were estimated as (episode rate) × (DRG cost weight per episode) × (2007 population) × (national price per cost weight).

Results

Episode rates for pneumococcal meningitis, bacteraemia and pneumonia were stable in 2000–7, highest in the second 6 months of life and declined steeply over the first 5 years of life. Mean rates per 100 000 in 2000–7 were 18.4, 27.6 and 464 for pneumococcal meningitis, bacteraemia and pneumonia, respectively, for children aged <2 years; 8.4, 14.9 and 295 for children aged <5 years (including those aged <2 years); and 2.2, 4.4 and 97 for children aged <20 years (including those aged <5 years). Mean rates per 100 000 in 2006–7 for Sp. and NTHi otitis media combined were 631 (surgical) and 197 (medical) for children aged <2 years; 691 and 116 for children aged <5 years; and 281 and 35 for children aged <20 years. Pacific Island and indigenous Māori children generally had higher rates than European/other children. Rates increased with socioeconomic disadvantage, across all diagnoses. The annual cost to Government of pneumococcal disease and NTHi otitis media admissions for children aged <20 years was estimated at New Zealand dollars ($NZ)9.95 million (range 7.7–12.2 million) [about $US7.1 million]. Most of this cost was shared between pneumococcal pneumonia (48%) and otitis media (45%), and 78% was incurred in the first 2 years of life. Estimated annual paediatric mortality rates per 100 000 for children aged <5 years were 0.48, 0.30 and 0.54 for pneumococcal meningitis, bacteraemia and pneumonia, respectively. The analysis predicted four or five pneumococcal deaths per year (range 1–8) for children aged <5 years.

Conclusions

Prior to the introduction of a national Sp. immunization programme, hospital admissions for Sp. disease and NTHi otitis media in NZ cost about $NZ10 million annually, mostly for children aged <2 years and particularly for those living in relative socioeconomic deprivation and for Pacific Island and Māori children. There were about five pneumococcal deaths annually. With adjustment for local serotypes, vaccine serotype coverage and uptake, immunization with any of the three available pneumococcal vaccines would reduce this burden substantially.

References

  1. 1.
    Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect 2006 Jan; 52(1): 37–48PubMedCrossRefGoogle Scholar
  2. 2.
    Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001 Apr 4; 285(13): 1729–35PubMedCrossRefGoogle Scholar
  3. 3.
    Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002 Apr; 161(4): 188–95PubMedCrossRefGoogle Scholar
  4. 4.
    Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006 Apr 12; 295(14): 1668–74PubMedCrossRefGoogle Scholar
  5. 5.
    Roche PW, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008 Mar; 32(1): 18–30Google Scholar
  6. 6.
    Winters M, Patrick DM, Marra F, et al. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can J Public Health 2008 Jan-Feb; 99(1): 57–61PubMedGoogle Scholar
  7. 7.
    Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Paediatrics 2009 Jun; 123(6): e1103–10CrossRefGoogle Scholar
  8. 8.
    Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp Rev Vaccines 2009 Aug; 8(8): 977–86CrossRefGoogle Scholar
  9. 9.
    Schuerman L, Borys D, Hoet B, et al. Prevention of otitis media: now a reality? Vaccine 2009 25; 27(42): 5748–54PubMedCrossRefGoogle Scholar
  10. 10.
    Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006 Mar 4; 367(9512): 740–8PubMedCrossRefGoogle Scholar
  11. 11.
    WHO. Pneumococcal vaccines: WHO position paper. Wkly Epidemiol Rec 1999; 74: 177–84Google Scholar
  12. 12.
    Heffernan HM, Martin DR, Woodhouse RE, et al. Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2008 Mar; 136(3): 352–9PubMedCrossRefGoogle Scholar
  13. 13.
    Voss L, Lennon D, Okesene-Gafa K, et al. Invasive pneumococcal disease in a paediatric population, Auckland, New Zealand. Pediatr Infect Dis J 1994 Oct; 13(10): 873–8PubMedCrossRefGoogle Scholar
  14. 14.
    Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005 Dec; 26(6): 563–74PubMedCrossRefGoogle Scholar
  15. 15.
    Levine OS, O’Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet 2006 Jun 10; 367(9526): 1880–2PubMedCrossRefGoogle Scholar
  16. 16.
    Craig E, Jackson C, Han D, et al. Monitoring the health of New Zealand children and young people. Auckland: Paediatric Society of New Zealand, New Zealand Child and Youth Epidemiology Service, 2007Google Scholar
  17. 17.
    O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009 12; 374(9693): 893–902PubMedCrossRefGoogle Scholar
  18. 18.
    Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997–2006. MMWR Morb Mort Wkly Rep 2009 Jan 16; 58(1): 1–4Google Scholar
  19. 19.
    Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008 16; 26(Suppl. 2): B19–23PubMedCrossRefGoogle Scholar
  20. 20.
    Morris PS, Leach AJ. Acute and chronic otitis media. Paediatr Clin North Am 2009 Dec; 56(6): 1383–99CrossRefGoogle Scholar
  21. 21.
    Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Paediatr Infect Dis J 2004 Dec; 23(12): 1142–52Google Scholar
  22. 22.
    Rosenblut A, Santolaya ME, Gonzalez P, et al. Bacterial and viral etiology of acute otitis media in Chilean children. Pediatr Infect Dis J 2001 May; 20(5): 501–7PubMedCrossRefGoogle Scholar
  23. 23.
    Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004 Sep; 23(9): 824–8PubMedCrossRefGoogle Scholar
  24. 24.
    Morris PS, Leach AJ, Halpin S, et al. An overview of acute otitis media in Australian Aboriginal children living in remote communities. Vaccine 2007 Mar 22; 25(13): 2389–93PubMedCrossRefGoogle Scholar
  25. 25.
    Leibovitz E, Satran R, Piglansky L, et al. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? Pediatr Infect Dis J 2003 Jun; 22(6): 509–15PubMedGoogle Scholar
  26. 26.
    Ministry of Health. Immunisation handbook. Wellington: Ministry of Health, 2006Google Scholar
  27. 27.
    Palmu A, Jokinen J, Kilpi T, et al. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 2008 12; 26(20): 2466–70PubMedCrossRefGoogle Scholar
  28. 28.
    Plasschaert AI, Rovers MM, Schilder AG, et al. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995–2003. Paediatrics 2006 Jun; 117(6): 1879–86CrossRefGoogle Scholar
  29. 29.
    Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006 Jun; 25(6): 494–501PubMedCrossRefGoogle Scholar
  30. 30.
    Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007 May; 18(2): 121–7PubMedGoogle Scholar
  31. 31.
    Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003 Jan; 22(1): 10–6PubMedCrossRefGoogle Scholar
  32. 32.
    Greville Consulting. New Zealand vision and hearing screening report July 2005–June 2006. Auckland: National Audiology Centre, 2006Google Scholar
  33. 33.
    Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 2004 Aug; 23(8): 732–8PubMedCrossRefGoogle Scholar
  34. 34.
    Jardine A, Menzies RI, Deeks SL, et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009 Sep; 28(9): 761–5PubMedCrossRefGoogle Scholar
  35. 35.
    World Health Organization. International statistical classification of diseases and related health problems, 10th revision, version for 2007: tabular list of inclusions and four-character subcategories [online]. Available from URL: http://apps.who.int/classifications/apps/icd/icd10online/ [Accessed 2010 Jul 22]
  36. 36.
    Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of hospitalised pneumonia in Lazio, Italy, 1997–1999. Int J Tuberc Lung Dis 2004 May; 8(5): 528–36Google Scholar
  37. 37.
    Dagan R. Pneumococcal conjugate vaccines probe studies: the solution points to the problem. Adv Exp Med Biol 2009; 634: 69–77PubMedCrossRefGoogle Scholar
  38. 38.
    Jackson CJ, Lennon D, Heffernan H, et al. Estimating invasive pneumococcal disease burden in New Zealand children: comparison of hospitalisation data with active and passive surveillance data. 7th International Symposium on Pneumococci and Pneumococcal Paediatric Diseases; 2010 Mar 14–18; Tel AvivGoogle Scholar
  39. 39.
    Barkai G, Leibovitz E, Givon-Lavi N, et al. Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Paediatr Infect Dis J 2009 Jun; 28(6): 466–71CrossRefGoogle Scholar
  40. 40.
    Salmond C, Crampton P, Atkinson J. NZDep2006: index of deprivation 2007. Wellington: Department of Public Health, Wellington School of Medicine and Health Sciences, 2007 [online]. Available from URL: http://www.uow.otago.ac.nz/academic/dph/research/NZDep/NZDep2006%20research%20report%2004%20September%202007.pdf [Accessed 2010 Jul 22]Google Scholar
  41. 41.
    Statistics New Zealand [online]. Available from URL: http://www.stats.govt.nz/ [Accessed 2010 Jul 22]
  42. 42.
    Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007 Dec; 161(12): 1162–8PubMedCrossRefGoogle Scholar
  43. 43.
    Jefferson T, Ferroni E, Curtale F, et al. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years of age. Lancet Infect Dis 2006 Jul; 6(7): 405–10PubMedCrossRefGoogle Scholar
  44. 44.
    Petit G, De Wals P, Law B, et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003 Jul; 14(4): 215–20PubMedGoogle Scholar
  45. 45.
    Salleras L, Dominguez A. Streptococcus pneumoniae incidence in western Europe. Lancet Infect Dis 2007 Apr; 7(4): 242–3PubMedCrossRefGoogle Scholar
  46. 46.
    Leibovitz E, Greenberg D. Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J 2004 Jul; 27(7): 475–88PubMedGoogle Scholar
  47. 47.
    Grant C, Milne R. What does pneumonia cost New Zealand? In: Asher I, Byrnes C, editors. Catching our breath. Auckland: Paediatric Society of New Zealand, 2006: 12–3Google Scholar
  48. 48.
    Grant CC, Scragg R, Tan D, et al. Hospitalization for pneumonia in children in Auckland, New Zealand. J Paediatr Child Health 1998 Aug; 34(4): 355–9PubMedCrossRefGoogle Scholar
  49. 49.
    Payne SM, Donahue C, Rappo P, et al. Variations in paediatric pneumonia and bronchitis/asthma admission rates. Arch Pediatr Adolesc Med 1995 Feb; 149(2): 162–9PubMedCrossRefGoogle Scholar
  50. 50.
    Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008 May; 86(5): 408–16PubMedCrossRefGoogle Scholar
  51. 51.
    Giles M, Asher I. Prevalence and natural history of otitis media with perforation in Maori school children. J Laryngol Otol 1991 Apr; 105(4): 257–60PubMedCrossRefGoogle Scholar
  52. 52.
    Giles M, O’Brien P. The prevalence of hearing impairment amongst Maori schoolchildren. Clin Otolaryngol Allied Sci 1991 Apr; 16(2): 174–8PubMedCrossRefGoogle Scholar
  53. 53.
    Giles M, O’Brien P. Otitis media and hearing loss in the children of the Ruatoki valley: a continuing public health problem. N Z Med J 1989 12; 102(865): 160–1PubMedGoogle Scholar
  54. 54.
    Ministry of Health. Immunisation coverage: national and DHB data [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-coverage-data [Accessed 2010 Jul 22]
  55. 55.
    Djuretic T, Ryan MJ, Miller E, et al. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect 1998 Jul; 37(1): 54–8PubMedCrossRefGoogle Scholar
  56. 56.
    Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Paediatr Infect Dis J 2006 Sep; 25(9): 779–81CrossRefGoogle Scholar
  57. 57.
    LeBas SJ, Grier LR, Campbell GD, et al. Nosocomial pneumonia. Curr Opin Pulm Med 1996 May; 2(3): 206–12PubMedCrossRefGoogle Scholar
  58. 58.
    Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005 Mar 26-Apr 1; 365(9465): 1139–46PubMedCrossRefGoogle Scholar
  59. 59.
    Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003 Oct 2; 349(14): 1341–8PubMedCrossRefGoogle Scholar
  60. 60.
    Madhi SA, Kuwanda L, Cutland C, et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005 15; 40(10): 1511–8PubMedCrossRefGoogle Scholar
  61. 61.
    Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009 12; 374(9693): 903–11PubMedCrossRefGoogle Scholar
  62. 62.
    Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001 Oct; 39(10): 3495–8PubMedCrossRefGoogle Scholar
  63. 63.
    Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369(9568): 1179–86PubMedCrossRefGoogle Scholar
  64. 64.
    Mackenzie GA, Carapetis JR, Morris PS, et al. Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. J Paediatr Child Health 2005 Apr; 41(4): 201–8PubMedCrossRefGoogle Scholar
  65. 65.
    Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989 Jul; 160(1): 83–94PubMedCrossRefGoogle Scholar
  66. 66.
    Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004 22; 22(31-32): 4203–14PubMedCrossRefGoogle Scholar
  67. 67.
    Jansen A. Pneumococcal infection in preschool children: incidence of acute otitis media and pneumonia related to influenza and respiratory syncytila virus circulation [abstract]. Presented at the ISPPD 5th International Symposium on Pneumococci and Pneumococcal Diseases; 2006 Apr 2–6; Alice Springs (NT)Google Scholar
  68. 68.
    Caceres Udina MJ, Varez Martinez JA, Chumilla Valderas MA, et al. Incidence, air pollution and risk factors of acute otitis media in the first year of life: a prospective study. An Pediatr (Barc) 2004; 60: 133–8CrossRefGoogle Scholar
  69. 69.
    Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 8; 344(6): 403–9PubMedCrossRefGoogle Scholar
  70. 70.
    Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunisation schedule. Value Health 2009 Sep; 12(6): 888–98PubMedCrossRefGoogle Scholar
  71. 71.
    Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001 8; 323(dy7312): 533–6PubMedCrossRefGoogle Scholar
  72. 72.
    Ministry of Health. Discharges from privately funded hospitals: 1 July 2004 to 30 June 2005 [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/discharges-privately-funded-hospitals-0405-nov09 [Accessed 2010 Jul 22]
  73. 73.
    Grijalva CG, Griffin MR. Population-based impact of routine infant immunisation with pneumococcal conjugate vaccine in the USA. Exp Rev Vaccines 2008 Feb; 7(1): 83–95CrossRefGoogle Scholar
  74. 74.
    Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med 2003 1; 348(18): 1737–46PubMedCrossRefGoogle Scholar
  75. 75.
    Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Paediatrics 2008 Feb; 121(2): 253–60CrossRefGoogle Scholar
  76. 76.
    Grijalva CG. Recognising pneumonia burden through prevention. Vaccine 2009 21; 27(Suppl. 3): C6–8PubMedCrossRefGoogle Scholar
  77. 77.
    Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. JAMA 2005 Oct 26; 294(16): 2043–51PubMedCrossRefGoogle Scholar
  78. 78.
    Centers for Disease Control (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal vaccine on incidence of invasive pneumococcal disease: United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893–7Google Scholar
  79. 79.
    Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunisation with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Paediatrics 2006 Sep; 118(3): 865–73CrossRefGoogle Scholar
  80. 80.
    Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Paediatr Infect Dis J 2005 Jan; 24(1): 10–6CrossRefGoogle Scholar
  81. 81.
    Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26(38): 4947–54PubMedCrossRefGoogle Scholar
  82. 82.
    Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [comment]. Paediatr Infect Dis J 2000; 19(3): 187–95CrossRefGoogle Scholar
  83. 83.
    Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002 Dec; 161Suppl. 2: S127–31PubMedCrossRefGoogle Scholar
  84. 84.
    Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Paediatr Infect Dis J 2002 Mar; 21(3): 182–6CrossRefGoogle Scholar
  85. 85.
    Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009; 11(5): 349–57.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.School of Population Health, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  2. 2.Department of StatisticsUniversity of AucklandAucklandNew Zealand

Personalised recommendations